Coherus BioSciences has confirmed that it has launched its pegfilgrastim biosimilar, Udenyca, in the United States market.
Coherus BioSciences has confirmed that it has launched its pegfilgrastim biosimilar, Udenyca, in the United States market.
In an email to The Center for Biosimilars®, a representative from Coherus confirmed that the California-based biosimilar developer, in keeping with its corporate plans, began sales of the biosimilar on January 3. The company previously announced that it would launch its product at a list price of $4175 per unit, or a 33% discount to the reference pegfilgrastim, Neulasta.
The biosimilar’s list price matches that of Mylan’s Fulphila, the first pegfilgrastim biosimilar to launch in the United States. Despite the fact that Coherus has matched Mylan on list price for the pegfilgrastim product, these prices do not reflect any additional rebates or discounts that the drug makers may offer as a means to differentiate their products in the US marketplace.
Coherus also recently signed a 340B prime vendor program contract with Apexus LLC. Apexus is the Health Resources and Services Administration’s designated prime vendor for the 340B Drug Pricing Program, under which it contracts with nearly all of the 340B-eligible covered entities, and the 340B channel accounts for approximately 35% of the reference pegfilgrastim units sold in the United States. The agreement coincided with Coherus’ receipt of a Q code from CMS and the company’s application of a transitional pass-through payment status for hospital outpatient settings.
With its first biosimilar now launched in the US market, Coherus is now looking to the future. On January 1, Darlene Horton, MD, joined the company as chief medical and regulatory affairs officer.
“We are very pleased that Dr. Horton has joined the executive team at Coherus,” said Denny Lanfear, chairman, president, and CEO of Coherus, in a statement. “She is a foremost biotechnology leader and clinician with an exceptional track record of delivering value to patients and shareholders.”
Among the biosimilar projects that will fall under Horton’s purview in the months ahead are CHS-1420, a proposed adalimumab biosimilar that has completed its phase 3 clinical study in psoriasis; CHS-0214, a proposed etanercept biosimilar that has completed phase 3 clinical studies in both psoriasis and rheumatoid arthritis; CHS-3351, a proposed ranibizumab biosimilar in preclinical development; and CHS-2020, a proposed aflibercept biosimilar in preclinical development.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.